An interventional study of IMPROVE in COVID-19, sponsored by Temple University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Temple University · Not applicable, Interventional, and Screening
The study aims to engage community partners to implement IMPROVE intervention and promote (COVID-19) rapid testing among vulnerable Asian Americans in the Greater Philadelphia Area and New York City
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 1,277 is above the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Temple University is the lead sponsor of 219 studies on the registry; 30 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 7 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
-
The earliest group to implement the IMPROVE intervention ( in 4-9 study months). Clusters assigned to this sequence remained in the control condition for 3 months, received the intervention for 6 months, and completed follow-up assessments for 3 months.
Behavioral: IMPROVE
Following the wedge 1 group, the wedge 2 group started the intervention in the study months 7-12. Clusters assigned to this sequence remained in the control condition for 6 months, received the intervention for 6 months, and completed follow-up assessments for 3 months.
Behavioral: IMPROVE
The wedge 3 group started the intervention in the study months 10-15. Clusters assigned to this sequence remained in the control condition for 9 months, received the intervention for 6 months, and completed follow-up assessments for 3 months.
Behavioral: IMPROVE
IMPROVE is a CBHN-led intervention. The study team delivered comprehensive training to CHNs to let them be well-prepared for intervention delivery. CHNs lead an in-person start-up group education session that consists of 4 modules: 1) a 6-minutes video of a health care provider delivering information on COVID-19 to help participants better understand the disease; 2) using educational slides, CHNs discuss the importance of COVID-19 testing and mitigation adherence; 3) CHNs conduct live demonstration of how to use rapid COVID-19 self-test kit correctly and distribute two COVID-19 self-testing kits to each participant. 4) CHNs guide interactive discussions with participants to enable them to reflect and reinforce what they learned. In addition, CHNs will help participants identify their navigation needs in reducing hesitancy of self-testing and mitigation practices. CHNs will also schedule check-in calls with participants.
Lifetime Rate of COVID-19 Home Self-Testing Kit Use
Lifetime use defined as self-report of ever using a COVID-19 rapid antigen home self-test kit at least once. Baseline was collected before IMPROVE implementation for all participants. The 1-month and 3-month follow-up assessments were collected after participants received the IMPROVE intervention, according to their wedge rollout schedule. Cleaned dataset with corrected data collection dates was used to update the results.
Time frame: baseline, 1-month follow up, and 3-month follow up
| Milestone | Wedge 1 | Wedge 2 | Wedge 3 |
|---|---|---|---|
| Started | 389 | 527 | 361 |
| Completed | 389 | 527 | 361 |
| Not completed | 0 | 0 | 0 |
| Milestone | Wedge 1 | Wedge 2 | Wedge 3 |
|---|---|---|---|
| Started | 389 | 527 | 361 |
| Completed | 389 | 527 | 361 |
| Not completed | 0 | 0 | 0 |
| Milestone | Wedge 1 | Wedge 2 | Wedge 3 |
|---|---|---|---|
| Started | 389 | 527 | 361 |
| Completed | 309 | 453 | 298 |
| Not completed | 80 | 74 | 63 |
| Withdrew: Lost to follow-up | 80 | 74 | 63 |
Lifetime use defined as self-report of ever using a COVID-19 rapid antigen home self-test kit at least once. Baseline was collected before IMPROVE implementation for all participants. The 1-month and 3-month follow-up assessments were collected after participants received the IMPROVE intervention, according to their wedge rollout schedule. Cleaned dataset with corrected data collection dates was used to update the results.
| Participants | Control | IMPROVE |
|---|---|---|
| Baseline (Control Period) | 430 | 0 |
| 1-month follow up | 0 | 583 |
| 3-month follow up | 0 | 732 |
Collected over Adverse events were monitored from enrollment through completion of post-intervention follow-up assessments, up to 15 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control | 0/1,277 (0%) | 0/1,277 (0%) | 0/1,277 (0%) |
| IMPROVE | 0/1,277 (0%) | 0/1,277 (0%) | 0/1,277 (0%) |
| Follow Up | 0/1,060 (0%) | 0/1,060 (0%) | 0/1,060 (0%) |
| Age, Continuous(years) | Wedge 1 | Wedge 2 | Wedge 3 | Total |
|---|---|---|---|---|
| Mean | 62.51 (19 to 94) | 59.63 (18 to 99) | 61.85 (18 to 94) | 61.13 (18 to 99) |
| Sex: Female, Male(Participants) | Wedge 1 | Wedge 2 | Wedge 3 | Total |
|---|---|---|---|---|
| Female | 290 | 363 | 210 | 863 |
| Male | 78 | 153 | 133 | 364 |
| Race (NIH/OMB)(Participants) | Wedge 1 | Wedge 2 | Wedge 3 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 389 | 527 | 361 | 1277 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Temple University